
|Articles|February 5, 2015
Accelovance Acquires European CRO
Accelovance, Inc. , a CRO therapeutically aligned in the areas of Oncology, Vaccines, and General Medicine; today announced it has acquired Altair Clinical, Ltd.
Advertisement
Accelovance, a therapeutically aligned CRO in the areas of oncology, vaccines, and general medicine; announced it has acquired Altair Clinical, a full service European clinical CRO and provider of global clinical CRO resourcing solutions to pharmaceutical, biotech, and medical device companies. The acquisition expands Accelovance's existing US and Beijing, China offices to include Cambridge, UK, Moscow, Russia, and staff located throughout Europe including Central and Eastern Europe (CEE) and the Middle East and North Africa (MENA).
Read the full release
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ICON Selects Microsoft as Preferred Technology Partner to Scale Agentic AI Platform Across Clinical Trial Lifecycle
2
ACT Brief: ICON-Microsoft AI Partnership, DCT Site Burden, and AI-Enabled Neuroimmune Discovery
3
ACT Brief: Mixed FSP Strategy, DIA Meeting Trends, and Patient Voice in Oncology
4
HHS Launches Operation TrialBlazer to Restore US Leadership in Clinical Research
5




